← Back to Clinical Trials
Recruiting NCT04787575

Oxygen-ozone Therapy Plus Antibiotic Therapy in the Treatment of Infections Secondary to Implant of Orthopaedic Devices

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Infection
Sponsor Società Scientifica Internazionale di Ossigeno Ozono Terapia
Study Type INTERVENTIONAL
Phase N/A
Enrollment 186
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-01-24
Completion 2025-09
Interventions
Oxygen-ozone therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This is an open-label, multicentre, randomized, parallel group study to evaluate the efficacy of treatment with oxygen-ozone therapy plus oral antibiotic therapy, in comparison with oral antibiotic therapy alone, in the proportion of patients with resolution/improvement of signs and symptoms of infection of the wound (e.g. ulcer, eschar, sore) in the target lesion after 14 days of treatment, in patients with infections secondary to implant of orthopaedic devices.

Eligibility Criteria

Inclusion Criteria: 1. Signed written informed consent; 2. Male or female aged ≥ 18 years; 3. Patient having undergone surgery for implant of an orthopaedic device in the previous 8 weeks; 4. Presence of at least one (but no more than 3) post-operative wounds in the site of surgery (ulcers, eschars, sores); 5. Presence of at least one symptom (pain, burning, redness and malodour) and at least one sign (erythema, local warmth, swelling, purulent secretion) of infection of at least moderate intensity (score ≥ 2) in the target lesion at the screening visit (Visit 1), to be confirmed again at the baseline visit (Visit 2); 6. Wound area of the target lesion ≤ 100 cm2; 7. Patient with presence at least one pathogen identified in the swab collection in the target lesion, which is amenable to be eradicated with oral antibiotic therapy; 8. In case of multiple wounds (however not more than three), non-target lesions must not overlap with the target one (i.e. the largest one); 9. Patient able to

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}